Banyan Biomarkers, Inc., an Alachua FL-based company focused on developing a blood test, completed a $6m series A funding from private investors.
The company intends to use the funds for further biomarker research and continued development of a traumatic brain injury (TBI) diagnostic test.
Led by Jackson Streeter M.D., CEO, Banyan Biomarkers is developing a simple point-of-care blood test that could be used by physicians to detect the presence of mild and moderate brain trauma and improve the medical management of head injured patients. The test uses two protein biomarkers licensed from the McKnight Brain Institute at the University of Florida.
The company is enrolling subjects in a 2,000 patient pivotal clinical trial funded by a $26.3m contract with the United States Department of Defense.